In Vitro Study of Encapsulation Therapy for Fabry Disease Using Genetically Engineered CHO Cell Line
Fabry disease is an X-linked recessive disorder caused by a deficiency of the lysosomal hydrolase α-galac-tosidase A (α-gal). The deficiency of this enzyme leads to the systemic deposition of ceramide trihexoside (CTH) in various tissues and organs. Enzyme replacement using IV doses of recombinant h...
Main Authors: | Y. Naganawa, K. Ohsugi, R. Kase, I. Date, H. Sakuraba, N. Sakuragawa M.D., Ph.D. |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2002-05-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.3727/000000002783985846 |
Similar Items
-
About making a CHO production cell line “research-friendly” by genetic engineering
by: Voedisch Bernd, et al.
Published: (2011-11-01) -
The Kidney in Fabry Disease
by: Hernán Trimarchi MD, PhD
Published: (2016-05-01) -
Enzyme Replacement Therapy for Fabry Disease
by: Maria Dolores Sanchez-Niño PhD, et al.
Published: (2016-11-01) -
Intracerebral Transplantation of Genetically Engineered Cells for Parkinson's Disease: Toward Clinical Application
by: Takao Yasuhara M.D., Ph.D., et al.
Published: (2007-02-01) -
In Vitro Genotoxic effects of Zerumbone and Cisplatin Combination in CHO Cell lines
by: Adel Sharaf Al-Zubairi
Published: (2017-11-01)